Paper Details

  1. Home
  2. Paper Details

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.

Author: ByrnesCharnel C, ChenHuiqin, DiPeriTimothy P, EvansKurt W, HalimAbdel-Baset, HiraiHiroshi, JavleMilind, KahleMichael P, KwongLawrence N, LeeSunyoung S, Meric-BernstamFunda, MossTyler, RodonJordi, ScottStephen, VaradarajanKaushik, WacheckVolker, ZhaoMing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated mechanisms of acquired resistance to fibroblast growth factor receptor (FGFR) inhibitors (FGFRi) in patients with FGFR2-fusion-positive cholangiocarcinoma. The study found that convergent genomic evolution in the MAPK pathway may be a mechanism of acquired resistance.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: There is a knowledge gap in understanding mechanisms of resistance to fibroblast growth factor receptor (FGFR) inhibitors (FGFRi) and a need for novel therapeutic strategies to overcome it. We investigated mechanisms of acquired resistance to FGFRi in patients with FGFR2-fusion-po...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jhep.2023.10.041

データ提供：米国国立医学図書館（NLM）

Overcoming Resistance to FGFR Inhibitors in Cholangiocarcinoma

This research investigates mechanisms of acquired resistance to fibroblast growth factor receptor (FGFR) inhibitors (FGFRi) in patients with FGFR2-fusion-positive cholangiocarcinoma (CCA). The study found that resistance to FGFRi is often associated with new mutations in the MAPK pathway, suggesting that targeting this pathway may be a promising strategy for overcoming resistance. The authors also found that combining FGFRi with MEK inhibitors can have synergistic antitumor activity in vitro, indicating a potential therapeutic approach for managing resistance to FGFRi.

The Evolving Landscape of Cancer Treatment

This research highlights the complex and evolving nature of cancer treatment. The study found that patients with FGFR2-fusion-positive cholangiocarcinoma (CCA) can develop resistance to FGFR inhibitors (FGFRi), highlighting the need for new therapeutic strategies. The findings suggest that targeting the MAPK pathway may be crucial for overcoming resistance and improving treatment outcomes. This research underscores the ongoing need for research and development of new cancer therapies to address the challenges of drug resistance.

Personalized Cancer Treatment

This research emphasizes the importance of personalized cancer treatment, which involves tailoring therapy to the specific characteristics of a patient's tumor. The study found that acquired resistance to FGFR inhibitors can occur in patients with FGFR2-fusion-positive cholangiocarcinoma (CCA). This underscores the need for close monitoring of patients and adapting treatment strategies as needed. As researchers, we are constantly working to develop new approaches to personalized cancer treatment, aiming to improve outcomes and enhance the lives of patients.

Dr.Camel's Conclusion

This research sheds light on the mechanisms of acquired resistance to FGFR inhibitors in FGFR2-fusion-positive cholangiocarcinoma (CCA). The findings suggest that mutations in the MAPK pathway contribute to resistance and that targeting this pathway may be a promising strategy for overcoming resistance.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-11-16
Further Info :

Pubmed ID

37972659

DOI: Digital Object Identifier

10.1016/j.jhep.2023.10.041

Related Literature

Article Analysis
・Effects of futibatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.